The notices it replaced
- Reissues: PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed
- 2 steps back: PA-18-574 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 3 steps back: PA-17-302 PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 4 steps back: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 5 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 6 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 10 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 11 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 12 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-21-259.
Who won it before
5,656 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,216,639,152 in first-year total cost, median $256,503.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]284
- Special Emphasis Panel[ZRG1 ETTN-G (12)]236
- Special Emphasis Panel[ZRG1 IMST-H (15)]202
- Special Emphasis Panel[ZRG1 IDM-V (12)]185
- Special Emphasis Panel[ZRG1 IMST-B (12)]179
Most frequent institutions
- PHYSICAL SCIENCES, INC36
- EPICYPHER, INC.35
- AFFINERGY, LLC30
- LYNNTECH, INC.26
- PROGENRA, INC.23
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Human Disease-Specific Induced Pluripotent Stem Cells For Preclinical Drug Testing and Drug Discovery1R44HL158281-01A1 | BUI, LYNNE A | KHLORIS BIOSCIENCES, INC., CA | $1,728,439 | ZRG1 |
| 2022 | A Safe, Fast, and Cost-Effective System for Tissue Removal in Laparoscopic Hysterectomy and Other Minimally Invasive Surgery1R44HD105575-01A1 | FRANCIS, DANIEL | CLARIA MEDICAL, INC., CA | $1,569,462 | ZRG1 |
| 2022 | Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)2R44GM117682-04 | SHINKAZH, OLEG | CHROMATAN CORPORATION, MA | $1,284,233 | ZRG1 |
| 2022 | Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media1R44DC019874-01 | MCOSKER, CHARLES C. | CLARAMETYX BIOSCIENCE, INC., OH | $1,207,921 | ZRG1 |
| 2022 | Novel patient-derived 3D platform for detecting TDP-43 proteinopathy and associated biomarkers for ALS/FTD1R44NS124457-01A1 | DE MAJO, MARTINAULLIAN, ERIK M | SYNAPTICURE, INC., IL | $1,171,621 | ZRG1 |
| 2022 | STARLIGHT, The Next Generation X-ray Imaging Technology1R44CA268468-01 | SILVER, ERIC | IMAGINE SCIENTIFIC, INC., MA | $1,057,480 | ZRG1 |
| 2022 | PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction1R44HL162139-01 | VOSKERICIAN, GABRIELA | OPTIMA INTEGRATED HEALTH, INC., CA | $1,034,876 | ZRG1 |
| 2022 | Engineered super-affinity reagents for detection of histone post-translational modifications1R44GM145007-01 | SUN, ZU-WEN | EPICYPHER, INC., NC | $1,024,329 | ZRG1 |
| 2022 | IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus1R44AI167461-01 | HUTCHINS, JEFF T | INHALON BIOPHARMA, INC., NC | $1,023,232 | ZRG1 |
| 2022 | Clinical Decision Support for Assessing Pulmonary Embolism using Machine Learning2R44HL152825-02 | KRAMER, KEVIN M. | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $1,018,633 | ZRG1 |
| 2022 | Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis1R44HL158435-01A1 | HARTMAN, JAMES CRAIG | MDI THERAPEUTICS, INC., MI | $1,000,618 | ZRG1 |
| 2022 | Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis2R44AI149833-03 | HANNAN, THOMAS JOSEPH | FIMBRION THERAPEUTICS, INC., MO | $1,000,000 | ZRG1 |
| 2022 | CMC of Peptide Formulation for the Treatment of ARDS1R44HL156295-01A1 | CASTILLO, GERARDO M. | PHARMAIN CORPORATION, WA | $999,993 | ZRG1 |
| 2022 | Preventing outbreaks of foodborne pathogenic bacteria in edible sprouts via novel resistance-conferring seed treatments2R44AI152915-02 | MANOHAR, MURLI | ASCRIBE BIOSCIENCE INC., NY | $998,060 | ZRG1 |
| 2022 | MetaboQuest: A Suite of Tools for Metabolite Annotation1R44GM145195-01 | MENGISTU, DAWITRESSOM, HABTOM W | OMICSCRAFT, LLC, DC | $997,931 | ZRG1 |
| 2022 | Development and validation of a sample-to-answer metagenomics workflow for comprehensive pathogen detection in central nervous system infections1R44AI167334-01 | GOURGUECHON, STEPHANE | ARC BIO, LLC, MA | $997,735 | ZRG1 |
| 2022 | Microscope system for large scale optical imaging of neuronal activity using kilohertz frame rates1R44MH129023-01 | GLASER, JACOB R | MICROBRIGHTFIELD, LLC, VT | $995,291 | ZRG1 |
| 2022 | iOP-Connect System for Long-Term Continuous Monitoring of Glaucoma Therapy by means of an Implantable Autonomous Intraocular Pressure Sensor1R44EY033565-01 | BERG, KEVIN DOUGLAS | INJECTSENSE, INC., CA | $993,500 | ZRG1 |
| 2022 | Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis1R44GM145103-01 | LIPKA, ELKE | TSRL, INC., MI | $988,469 | ZRG1 |
| 2022 | A recombinant matrix to improve autologous tissue grafts2R44CA244110-02A1 | ROBERTS, STEFAN | INSOMA BIO, INC., NC | $936,817 | ZRG1 |
| 2022 | Ultra-sensitive Vapor Phase Hydrogen Peroxide Sensor for Decontaminating Pharmaceutical Manufacturing Facilities2R44GM135957-02 | BRUMFIELD, BRIAN E | PHYSICAL SCIENCES, INC, MA | $928,483 | ZRG1 |
| 2022 | Introducing Neuroscience and Neurocomputation Concepts to High School Students using Brain-based Neurorobots2R44NS108850-03A1 | GAGE, GREGORY JOHNHARRIS, CHRISTOPHER AIDAN | BACKYARD BRAINS, INC., MI | $928,237 | ZRG1 |
| 2022 | Microfluidic technology for a full-page braille and graphical tactile display2R44EY030385-02A1 | RUSSOMANNO, ALEXANDER | NEWHAPTICS CORP., MI | $905,987 | ZRG1 |
| 2022 | New tools for highly accessible single cell RNA sequencing1R44GM145185-01 | FONTANEZ, KRISTINA | FLUENT BIOSCIENCES INC., MA | $903,654 | ZRG1 |
| 2022 | Transcatheter Device for Congestive Heart Failure Treatment Through Left Atrial Decompression2R44HL142440-02A1 | PATE, THOMAS DIFFLEY | ALLEVIANT MEDICAL, INC., TX | $898,558 | ZRG1 |
| 2022 | Commercializing the μSIM: A Modular Platform for the Development and Analysis of Barrier Tissue Models2R44GM137651-02 | ROUSSIE, JAMES ANDREW | SIMPORE, INC., NY | $893,657 | ZRG1 |
| 2022 | IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid1R44AI167132-01 | KU, MATTHEWSLATTERY, WILLIAM H | O-RAY PHARMA, INC., CA | $886,552 | ZRG1 |
| 2022 | HLS-Development of a cardiac ischemia model in an organ-on-a-chip platform2R44HL140920-02 | HICKMAN, JAMES JMCALEER, CHRISTOPHERSHULER, MICHAEL L | HESPEROS, LLC, FL | $854,765 | ZRG1 |
| 2022 | Development of an acoustofluidic device for high-throughput 3D imaging and sorting of C. elegans2R44OD024963-03 | WANG, LIN | ASCENT BIO-NANO TECHNOLOGIES, INC., NC | $851,323 | ZRG1 |
| 2022 | Efficient and scalable microfluidic gene delivery to hematopoietic stem cells to treat blood diseases2R44HL149598-02A1 | HAN, SEWOON | CELLFE INC., GA | $837,232 | ZRG1 |
| 2022 | ELIMINATION OF AIRBORNE VOLATILE COMPOUNDS THROUGH INCORPORATION OF ADVANCED 3D NANOSTRUCTURED CATALYTIC COATINGS IN ADSORPTION/DECOMPOSITION AIR PURIFICATION SYSTEMS2R44ES031893-02 | SHIRMAN, ELIJAH | METALMARK INNOVATIONS, PBC, MA | $795,659 | ZRG1 |
| 2022 | A comprehensive solution for native top down mass spectrometry data analyses across structural biology and biopharma2R44GM130262-02 | DURBIN, KENNETH | PROTEINACEOUS, INC., IL | $764,178 | ZRG1 |
| 2022 | Automated objective outcome measures for clinical use in dysarthria2R44DC017625-02A1 | CHARLES, SHERMAN | AURAL ANALYTICS, INC., AZ | $734,433 | ZRG1 |
| 2022 | Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment1R44EY033626-01 | DIBAS, ADNAN ISMAILMOHANTY, SAMARENDRA KUMAR | NANOSCOPE TECHNOLOGIES, LLC, TX | $716,879 | ZRG1 |
| 2022 | Leveraging Health Information Technology to Improve Trauma Resuscitation1R44LM013859-01 | METZLER, MICHAEL H. | LIFEBOARD MEDICAL, CO | $651,784 | ZRG1 |
| 2022 | Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer2R44CA250786-02 | ROTOLO, JIM | SAPIENCE THERAPEUTICS, INC., NY | $631,607 | ZRG1 |
| 2022 | Developing prototype injectability and developability testing system based on microfluidic quartz resonators2R44GM139438-02 | PARLAK, ZEHRA | QATCH TECHNOLOGIES, LLC, NC | $598,658 | ZRG1 |
| 2022 | CDK2 inhibitors for protecting hearing loss2R44DC018463-02A1 | ZALLOCCHI, MARISA L. | TING THERAPEUTICS, INC., CA | $566,238 | ZRG1 |
| 2022 | TBI identification and monitoring through retinal scanning2R44NS117553-02 | GOLDSTEIN, LEE E.SHAKA, JUSTIN | REBISCAN, LLC, MA | $517,500 | ZRG1 |
| 2022 | High-resolution genomic mapping of ssDNA and associated proteins for Alzheimer's disease research1R43AG076049-01 | KEOGH, MICHAEL-CHRISTOPHER | EPICYPHER, INC., NC | $500,000 | ZRG1 |
| 2022 | Reducing the prohibitive costs of protein production for therapeutic development2R44GM136097-02 | SHEPHERD, RYAN W. | PHYLLOTECH, LLC, WI | $500,000 | ZRG1 |
| 2022 | High-resolution 3D in situ Spatial Gene Expression Profiling Technology for Human Brain Specimens1R43AG076178-01 | DEWAL, MAHENDER BABUZHAN, BAO | EXPANSION TECHNOLOGIES, INC., MA | $500,000 | ZRG1 |
| 2022 | Magnetic Rotational Exploratory Platform for Coronary Lesions1R43HL158306-01A1 | BACH, RICHARD GORDONCREIGHTON, FRANCIS MILTON | UNANDUP, LLC, MO | $456,397 | ZRG1 |
| 2022 | Development of the Plasmin-independent Thrombolytic Agent for the Treatment of Acute Ischemic Stroke1R43NS125756-01 | KIM, HYEON JIN | SNJ PHARMA INC., CA | $449,594 | ZRG1 |
| 2022 | DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME1R43HL162218-01 | TANG, BEVERLY | STARLIGHT CARDIOVASCULAR, INC., CA | $448,000 | ZRG1 |
| 2022 | Development of a Minimally Invasive Partial Circulatory Support Device for Chronic Use1R43HL162109-01 | ABER, GREG | CORVION, INC., TX | $428,204 | ZRG1 |
| 2022 | Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping1R44HG011875-01A1 | KEOGH, MICHAEL-CHRISTOPHERVENTERS, BRYAN J | EPICYPHER, INC., NC | $426,207 | ZRG1 |
| 2022 | Direct Activation of PP2A as a Novel Approach to Group-3 Medulloblastoma Therapy1R43CA268329-01 | OHLMEYER, MICHAEL | ATUX ISKAY GROUP LLC, NJ | $406,500 | ZRG1 |
| 2022 | Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease1R43NS125730-01 | GANDHI, SUNIL | SAVANNA BIOTHERAPEUTICS, INC., CA | $399,859 | ZRG1 |
| 2022 | Micro-Organospheres Drug Screen to Lead Care (MODEL): a Precision Oncology Platform to Guide Breast Cancer Therapy1R44CA261579-01A1 | DELUBAC, DANIEL | XILIS, INC., NC | $398,486 | ZRG1 |
| 2022 | Lung Cancer, DNA Methylation, and Liquid Biopsy1R43CA257133-01A1 | NELSON, MARK ANTHONY | PRECISION EPIGENOMICS, INC., AZ | $397,831 | ZRG1 |
| 2022 | Liquid-infused tympanostomy tubes with novel material design for efficient drug transport1R43DC019318-01A1 | PAVLICHENKO, IDA | PIONEAR TECHNOLOGIES, INC., MA | $349,501 | ZRG1 |
| 2022 | Leaflet sparing transcatheter aortic valve equipped with IVUS-guided delivery system.1R43HL162385-01 | HOSMER, RONALD J | VALVENTION, INC., CA | $349,309 | ZRG1 |
| 2022 | A non-viral gene editing platform for cell therapies and translational autoimmune disease modeling1R43TR003743-01A1 | WIERSON, WESLEY | LIFENGINE ANIMAL HEALTH LABORATORIES INCORPORATED, MN | $337,433 | ZRG1 |
| 2022 | Evaluating Early and Late Functional, Immune and Angiogenic Responses to Injected Cardiac Fibroblast Derived Matrix in a Myocardial Infarction Model1R43HL162236-01 | SCHMUCK, ERIC GARY | CELLULAR LOGISTICS INC., WI | $337,094 | ZRG1 |
| 2022 | Development of Neuromodulating AAV-KCC2 Gene Therapy to Treat Paralysis, Spasticity and Neuropathic Pain after Spinal Cord Injury1R43NS124434-01A1 | HEGARTY, SHANE | AXONIS THERAPEUTICS, INC., MA | $335,668 | ZRG1 |
| 2022 | Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad1R43HL162135-01 | GLASS, CHARLES ALEXANDERTHACKER, BRYAN EDWARD | TEGA THERAPEUTICS, INC., CA | $321,866 | ZRG1 |
| 2022 | NeuroVision™: A Smartphone Application for Neurology and Telemedicine1R43NS125709-01 | SHIWANI, BHAWNA | ALTEC, INC., MA | $320,927 | ZRG1 |
| 2022 | Intravenous delivery of oxygen microbubbles for the treatment of hypoxia and ARDS1R43HL158362-01A1 | ARCAND, BENJAMIN | AGITATED SOLUTIONS, LLC, MN | $305,538 | ZRG1 |
| 2022 | Sustained Triumvirate Delivery by Contact Lens for Post-Surgical Management1R43EY033591-01 | ADAMS, CHRIS | DIOPTER TECHNOLOGIES, INC., MA | $305,500 | ZRG1 |
| 2022 | Novel assay to detect integrated HBV DNA in urine of chronic hepatitis B patients1R43AI167169-01 | LIN, SELENA | JBS SCIENCE, INC., PA | $305,372 | ZRG1 |
| 2022 | Development of a Novel Whole Genome Sequencing-based Platform for Rapid Identification and Antimicrobial Profiling of Uropathogens1R43AI167193-01 | BILLINGS, AMANDA NICOLE | DAY ZERO DIAGNOSTICS, INC., MA | $303,932 | ZRG1 |
| 2022 | Generalizable Protodrug Characteristics for In Vivo Drug Release using the Click Activated Protodrugs (CAP) Platform1R43TR004026-01 | ROYZEN, MAKSIMYEE, NATHAN | TAMBO, INC., CA | $300,224 | ZRG1 |
| 2022 | A Smart, Fully Subcutaneous Distraction System to Improve Outcomes in Patients with Congenital or Acquired Craniofacial Differences1R43DE031195-01A1 | DESNOYER, JESSICAWES, ARI M | OSTIIO LLC, PA | $300,000 | ZRG1 |
| 2022 | Targeting galectin-3 to intervene COVID-191R43AI162182-01A1 | AHMED, HAFIZ | GLYCOMANTRA, INC., MD | $300,000 | ZRG1 |
| 2022 | Development of a non-Factor small molecule, oral, prophylactic and hemostasis balanced therapy for treatment of clotting disorders including hemophilia A/B1R43HL162336-01 | GORE, MAKARAND PRABHAKAR | YEWSAVIN, INC., CO | $300,000 | ZRG1 |
| 2022 | Aerosol Ventilation to Reduce Ventilator Induced Lung Injury1R43HL162148-01 | JONES, ANDREW | BOUNDLESS SCIENCE, LLC, NC | $299,996 | ZRG1 |
| 2022 | Development and Pre-Clinical Testing of PEKK/Silicon Nitride Composite Craniomaxillofacial Implants1R43DE031456-01 | BOCK, RYAN | SINTX TECHNOLOGIES, INC., UT | $299,980 | ZRG1 |
| 2022 | Wearable Microfluidic Systems for Measuring Sweat Biomarkers in Cystic Fibrosis Patients During Exercise in Remote Settings1R43HL162246-01 | LEE, STEPHEN PETER | EPICORE BIOSYSTEMS, INC., MA | $299,936 | ZRG1 |
| 2022 | Discovery of bacterial consortia to treat recurrent vulvovaginal candidiasis: a generalizable platform for phenotypic microbial community screening1R43AI167131-01 | KEHE, JARED SCOTT | CONCERTO BIOSCIENCES, MA | $299,907 | ZRG1 |
| 2022 | A biophysical assay targeting SARS CoV-2 RNA1R43AI167095-01 | STORY, SANDRA PAIGE | NUBAD, LLC, SC | $299,900 | ZRG1 |
| 2022 | VesiVax Vaccine Formulation Against Neisseria gonorrhoeae1R43AI167312-01 | FUJII, GARY | MOLECULAR EXPRESS, INC., CA | $299,817 | ZRG1 |
| 2022 | Virtual Activities of Living for Occupational Rehabilitation1R43HD107718-01 | ADAMS, RICHARD J. | BARRON ASSOCIATES, INC., VA | $299,790 | ZRG1 |
| 2022 | A Lifestyle Program for Comorbid Obstructive Sleep Apnea with Severy Obesity1R43HL162131-01 | BENZO, ROBERTO PABLOKNUTSON, MATTHEW | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $299,345 | ZRG1 |
| 2022 | Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a1R43HL162137-01 | JACKSON, DAVID | CERIA THERAPEUTICS, INC., AZ | $299,271 | ZRG1 |
| 2022 | mRNA Delivery of a Panel of Single-Domain Antibodies for Combinatorial Deciphering of Therapeutic Targets for Covid-19 Related Cytokine Release Syndrome1R43AI162345-01A1 | GAO, XIANG | ONCOTRAP, INC., NC | $299,128 | ZRG1 |
| 2022 | Small Molecule E6 Inhibitors to Treat Dysplasia Caused by HPV Infections1R43AI167573-01 | ANDROPHY, ELLIOT J.LU, ZHIJIAN | KOVINA THERAPEUTICS INC., IN | $298,527 | ZRG1 |
| 2022 | Niclosamide Formulations for the Treatment of Influenza Infections1R43AI167394-01 | FUJII, GARY | MOLECULAR EXPRESS, INC., CA | $298,479 | ZRG1 |
| 2022 | Parkin activators for cardioprotective therapies1R43HL162163-01 | SURESH, KUMAR | PROGENRA, INC., PA | $296,932 | ZRG1 |
| 2022 | System for unitary automation of library preparation1R43GM145194-01 | FISHER, JAY KENNETH | REDBUD LABS, INC., NC | $292,788 | ZRG1 |
| 2022 | Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots1R43DC019890-01 | STOWE, RAYMOND PRESTON | MICROGEN, LLC, TX | $291,613 | ZRG1 |
| 2022 | Highly loaded long-acting depots of therapeutic peptides1R43TR004025-01 | PAGELS, ROBERT FREDERICK | OPTIMEOS LIFE SCIENCES, INC., NJ | $287,726 | ZRG1 |
| 2022 | Novel Extracorporeal Therapy for the Reversal of Septic Shock and Restoring Hemodynamic Stability1R43GM144973-01 | CHAN, PHILLIP | CYTOSORBENTS, INC., NJ | $281,835 | ZRG1 |
| 2022 | Recombinant botulinum toxin with improved safety and effectiveness for treatment of dystonia1R43NS122661-01A1 | BAND, PHILIP ARTHUR | CYTODEL, INC., NY | $276,617 | ZRG1 |
| 2022 | Novel biomaterial for enantiomer separation1R43GM145098-01 | PARHAM, CHRISTI | BONDWELL TECHNOLOGIES LP, TX | $275,766 | ZRG1 |
| 2022 | PillHarmonics: An Orchestrated Medication Clinical Decision Support Service1R43HG011832-01A1 | SHALABY, JAMES | ELIMU INFORMATICS, INC., CA | $274,586 | ZRG1 |
| 2022 | Discovery of inhibitors of EBV lytic cycle inducing protein ZTA for therapeutic development1R43AI167400-01 | YANO, TAKAHIRO | VIRONIKA, LLC, PA | $269,073 | ZRG1 |
| 2022 | A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children1R44HL162151-01 | PAMULA, VAMSEE K. | BAEBIES, INC., NC | $266,110 | ZRG1 |
| 2022 | Sourcerer IC: A Web-Based Integrative Multi-Modal Workflow for Epilepsy Surgical Planning1R44NS120591-01A1 | LUU, PHAN | BRAIN ELECTROPHYSIOLOGY LABORATORY COMPANY, LLC, OR | $262,362 | ZRG1 |
| 2022 | CardioTwin HCM: A non-genetic early diagnostic test for hypertrophic cardiomyopathy risk1R43HL162202-01 | RUPERT, CASSADY E. | PROPRIA LLC, CT | $259,609 | ZRG1 |
| 2022 | Computational algorithm to predict interacting MHC alleles from TCR sequences1R43GM143955-01A1 | CHEN, BINBIN | VCREATE, INC., CA | $256,581 | ZRG1 |
| 2022 | Real Time NEURON Simulation for Experimental Applications1R43NS125749-01 | NOWAK, MARK W | CYTOCYBERNETICS, INC., NY | $256,581 | ZRG1 |
| 2022 | Enhancing CRISPR-mediated homology-directed repair using anti-CRISPR proteins1R43GM145002-01 | RABUKA, DAVID | ACRIGEN BIOSCIENCES, INC., CA | $256,580 | ZRG1 |
| 2022 | An Online, Real-Time Microfluidic Biosensor for PFOA and PFOS1R43ES033873-01 | CSICSERY, NICHOLAS | QUANTITATIVE BIOSCIENCES, INC., CA | $256,580 | ZRG1 |
| 2022 | Development of novel ASO-based therapeutics for CMT1A1R43NS125717-01 | OCONNOR, STEVE | SHIFT PHARMACEUTICALS HOLDINGS, INC., MO | $256,580 | ZRG1 |
| 2022 | Improving influenza vaccines through wastewater-based macro-scale strain surveillance1R43AI167462-01 | KANE, SARAH JO | GT MOLECULAR, LLC, CO | $256,575 | ZRG1 |
| 2022 | Click City: Marijuana - An Interactive, Scalable, High-Fidelity, Digital Prevention Program for Youth1R43DA055376-01 | ANDREWS, JUDY AWESTLING, ERIKA | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $256,492 | ZRG1 |
| 2022 | Non-Contact Solution for Quantitative Clinical Management of MTD1R43DC019585-01 | VOJTECH, JENNIFER MICHELE | ALTEC, INC., MA | $256,439 | ZRG1 |
| 2022 | A Novel Targeted Therapy for Subarachnoid Hemorrhage1R43NS124491-01A1 | CHOUDHURY, KALIDIP | LOXAGEN INC., CA | $256,386 | ZRG1 |
| 2022 | Immunoplate-MALDI MS platform and assays1R43GM143964-01A1 | NEDELKOV, DOBRIN | ISOFORMIX, INC., TX | $256,158 | ZRG1 |
| 2022 | Therapeutic Immunodepletion of a Transthyretin Aggregation Intermediate1R43GM145259-01 | APOSTOL, MARCIN | ADRX, INC., CA | $256,083 | ZRG1 |
| 2022 | Dual Targeting Mitochondria and GPCR in Retinal Protection1R43EY033589-01 | ASH, JOHN DCHANG, QING | ARGOS VISION INC., IL | $255,710 | ZRG1 |
| 2022 | Non-Linear Optical femtosecond laser device to alter corneal curvature and stiffness.1R43EY032815-01A1 | KARAVITIS, MICHAEL | M2-COR, INC., CA | $255,671 | ZRG1 |
| 2022 | LentiTag: A novel approach to the efficient manufacturing of active lentiviral vectors1R43GM144018-01A1 | LUGINBUHL, KELLI MICHELLE | ISOLERE BIO, INC., NC | $255,556 | ZRG1 |
| 2022 | Develop a novel phase-change water/fluid purification technology that uses a NASA-validated vapor compression distillation (VCD)1R43ES033880-01 | BITTERLY, STEVE | STEVE BITTERLY, CA | $255,208 | ZRG1 |
| 2022 | SpeechSense: An Interactive Sensor Platform for Speech Therapy1R43DC019589-01 | DE LUCA, GIANLUCA | ALTEC, INC., MA | $254,556 | ZRG1 |
| 2022 | Development of a high performance, compact Snapshot Hyperspectral Camera with light integrator array1R43GM142353-01A1 | OLSZAK, ARTUR G | ATTORIS, LLC, TX | $252,041 | ZRG1 |
| 2022 | Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons.1R43NS125892-01 | KATIYAR, KRITIKA | AXONOVA MEDICAL, LLC, PA | $250,421 | ZRG1 |
| 2022 | Multi-omics profiling of individual exosomes for their origin-tracing, biomarker discovery, and biological function characterization1R43GM145015-01 | CHEN, YUCHAO | WELLSIM BIOMEDICAL TECHNOLOGIES, INC., CA | $249,974 | ZRG1 |
| 2022 | A Rapid Carotid Atherosclerotic Disease Assessment System with 3D MRI1R43HL156327-01A1 | XU, DONGXIANG | IMAGING BIOMARKER SOLUTIONS, INC., WA | $249,843 | ZRG1 |
| 2022 | Diffraction tomography for accurate digital pathology on a portable microscope1R43EB031714-01 | BOKADIA, PRATIK | AIRILABS LLC, NC | $249,045 | ZRG1 |
| 2022 | EyeStar-BIO: Software for Enhancing Digital Binocular Indirect Ophthalmoscopy Examinations1R43EY033569-01 | WIGDAHL, JEFFREY | VISIONQUEST BIOMEDICAL INC, NM | $247,627 | ZRG1 |
| 2022 | Novel antibody-drug conjugates targeting T-cell lymphoma1R43CA268668-01 | MILLER, JOHN P. | ASYLIA THERAPEUTICS, INC., TX | $246,451 | ZRG1 |
| 2022 | Anti-viral Active Air-Purifying Respirator with Photocatalytic Microreactor to Prevent Airborne Diseases1R43OH012358-01 | RAHMAN, ARIF | HAWAI'I INNOVATION LABORATORY, INC., HI | $243,500 | ZRG1 |
| 2022 | Development of an Instant Freezing Sample Preparation System for Cryo-EM1R43GM145044-01 | SALMON, NORMAN JAMES | HUMMINGBIRD PRECISION MACHINE COMPANY, WA | $237,305 | ZRG1 |
| 2022 | Method for Rapid Non-Invasive Assessment of Coronary Stenosis1R43HL162240-01 | NICKOLS, JOSH | VCARDIO INC, KY | $229,693 | ZRG1 |
| 2022 | A Low-Cost, Practical Fitness Monitor of Socket-Suspension Systems for Lower Limb Amputees1R43HD105511-01A1 | LIU, MING | ASSIST EQUIPMENT DEVELOPMENT, INC., NC | $225,397 | ZRG1 |
| 2022 | New Transformation Technology for Gene Editing of Human Mitochondrial DNA Associated With Mitochondrial Diseases1R43GM144983-01 | SAKAI, HAJIME | NAPIGEN, INC., DE | $225,000 | ZRG1 |
| 2022 | A microphysiological system with a synthetic hemoglobin, Blood Substitute, for mechanistic assessment of drug-induced liver injury1R43TR004290-01 | VUKASINOVIC, JELENA | LENA BIOSCIENCES, INC., GA | $221,075 | ZRG1 |
| 2022 | Production of Natural Deoxysugars for Chemical Synthesis of Glycosides1R43GM145102-01 | TURNER, ROBERT J. | MIDWEST BIOPROCESSING CENTER, LLC, IL | $217,421 | ZRG1 |
| 2022 | A closed-loop gravity infusion control device1R44NR019963-01A1 | KAWAHARA, CHIE | SHIFT LABS, INC., WA | $216,597 | ZRG1 |
| 2022 | Wearable Multi-Gas Technologies for Monitoring Personal Air Quality1R44ES033877-01 | BEDOLLA PANTOJA, MARCO A | PLATYPUS TECHNOLOGIES, LLC, WI | $205,103 | ZRG1 |
| 2022 | Deep learning augmented protein mapping software to screen large compound libraries1R43GM144992-01 | BEGLOV, DMITRI | ACPHARIS, INC., MA | $173,006 | ZRG1 |
| 2022 | A universal ambient air-oxygen blender to treat respiratory distress in newborns1R43HL162270-01 | CARVALHO, BRUCE LAWRENCE | POLYMERIX LLC, MA | $165,600 | ZRG1 |
| 2021 | Leadless Pacemaker Betavoltaic Power Source2R44HL145950-02A1 · under PA-19-272 | CABAUY, PETER | CITY LABS, INC., FL | $2,242,432 | ZRG1 |
| 2021 | Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics1R44NS124473-01 | SARRAF, STELLA | AMYDIS DIAGNOSTICS, INC., CA | $2,077,573 | ZRG1 |
| 2021 | Opening The Black Box: Enhancing Machine Learning Interpretability To Optimize Clinical Response To Sudden Deterioration In COVID-19 Patients1R44EB030955-01A1 | EDELSON, DANA PERES | AGILEMD, INC., CA | $1,995,966 | ZRG1 |
| 2021 | In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response1R44CA265752-01A1 | NGAMCHERDTRAKUL, WORAPOLYANTASEE, WASSANA | PDX PHARMACEUTICALS, INC., OR | $1,898,361 | ZRG1 |
| 2021 | Non-opiate topical formulations for treating pain associated with molar extractions2R44DE028208-02A1 · under PA-19-272 | PARR, ALAN | ARCATO LABORATORIES, INC., NC | $1,542,183 | ZRG1 |
| 2021 | Improved Treatment of Distal Radius Fractures Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive2R44AG060881-02 · under PA-19-272 | HESS, BRIAN | REVBIO, INC., MA | $1,368,425 | ZRG1 |
| 2021 | Highly Efficient MRI Pulse Sequences for High Resolution Physiological and Functional Brain Imaging1R44MH129278-01 | BECKETT, ALEXANDERFEINBERG, DAVID ALAN | ADVANCED MRI TECHNOLOGY, LLC, CA | $1,340,229 | ZRG1 |
| 2021 | Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery2R44GM130268-02 · under PA-19-272 | BORDBAR, AARASHNEMKOV, TRAVIS | SINOPIA BIOSCIENCES, INC., CA | $1,335,997 | ZRG1 |
| 2021 | Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique2R44HL147825-02A1 | BASUDE, RAGHUVEER | MEDFREE, INC., CA | $1,331,698 | ZRG1 |
| 2021 | Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors2R44CA224463-02A1 | BERKOWITZ, BARRY ADESIR, GARY V.KLUGER, HARRIET M. | BESSOR PHARMA, LLC, MA | $1,327,758 | ZRG1 |
| 2021 | Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer1R44CA265639-01 | THACHER, SCOTT MCNEAR | ORPHAGEN PHARMACEUTICALS, CA | $1,306,362 | ZRG1 |
| 2021 | A comprehensive quality control testing strategy for engineered cells1R44TR003554-01 · under PA-19-272 | TOMPKINS, CHRISTOPHER JOHN | KROMATID, INC., CO | $1,284,984 | ZRG1 |
| 2021 | Sustained Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity2R44NS110135-02 | MARTIN, FRANCIS JOSEPH | DELPOR, INC., CA | $1,280,691 | ZRG1 |
| 2021 | Wirelessly controlled BSL3 vivarium system for automated microdosing in studies of infectious diseases1R44OD031437-01 | HOANG, TUAN Q | FLUID SYNCHRONY, LLC, CA | $1,273,102 | ZRG1 |
| 2021 | A turnkey research platform to accelerate clinical translation of targeted immune-modulation enhanced therapies2R44CA239830-02A1 | CZERNUSZEWICZ, TOMASZ JOSEPHGESSNER, RYAN | SONOVOL, INC., NC | $1,237,360 | ZRG1 |
| 2021 | A New Device to measure Whole and Tissue Level Bone Strength.1R44AG071034-01 · under PA-19-272 | BURKS, PETERTANG, SIMON YUE-CHEONG | ACTIVE LIFE SCIENTIFIC, INC., CA | $1,213,580 | ZRG1 |
| 2021 | Flow Acceleration for Stroke Thrombolysis (FAST) System1R44NS122604-01 | CREIGHTON, FRANCIS MILTONHEMMEN, THOMAS M | UNANDUP, LLC, MO | $1,211,807 | ZRG1 |
| 2021 | New targeted BDNF nanoparticles for treatment of METH addiction and neurotoxicity2R44DA044050-02A1 | VITALIANO, FRANCOVITALIANO, GORDANA D. | EXQOR TECHNOLOGIES, INC., MA | $1,194,659 | ZRG1 |
| 2021 | Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis1R44NS124471-01A1 | WERNER, JOHN KENT | COGENTIS THERAPEUTICS, INC., MD | $1,183,364 | ZRG1 |
| 2021 | Development and validation of a novel non-invasive device for measuring the mechanical properties of cortical bone2R44AG058312-02 | CLARK, BRIAN CDICK, ANDREW | OSTEODX INC., OH | $1,165,903 | ZRG1 |
| 2021 | Automated Ultra-Long DNA and RNA Extraction for Long-read Sequencing Applications2R44GM131530-02A1 · under PA-19-272 | BROWN, MARK T | CLAREMONT BIOSOLUTIONS, LLC, CA | $1,164,571 | ZRG1 |
| 2021 | Development of chimeric read amplification into a robust method for profiling targets of specific microRNAs and global amplification of all microRNA:mRNA pairings transcriptome-wide2R44HG010603-02 | SHISHKIN, ALEXANDER A | ECLIPSE BIOINNOVATIONS INC, CA | $1,137,682 | ZRG1 |
| 2021 | An energy discriminating direct detector for multi-color SEM1R44MH125687-01A1 | BAMMES, BENJAMIN EUGENE | DIRECT ELECTRON, LP, CA | $1,104,885 | ZRG1 |
| 2021 | Optimization of a Novel Thread Geometry for Various Orthopedic Surgery Applications1R44AR079300-01A1 | FAUTH, ANDREW RAY | OSTEOCENTRIC TECHNOLOGIES, INC., TX | $1,104,366 | ZRG1 |
| 2021 | National Immunohistochemistry Standardization Program - Establishment & Launch1R44CA268484-01 | BOGEN, STEVEN A | BOSTON CELL STANDARDS INC, MA | $1,101,356 | ZRG1 |
| 2021 | New Arterial Sheath for Stroke and Other Neurovascular Interventions.1R44HL154876-01A1 | SYED, MUBIN | RAM MEDICAL INNOVATIONS, INC., OH | $1,095,695 | ZRG1 |
| 2021 | Generation of antibody-drug conjugates by proximity-based sortase-mediated ligation2R44CA221374-02 | YU, FEIFAN | ALPHATHERA, INC., PA | $1,081,188 | ZRG1 |
| 2021 | Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain1R44EY033267-01 | KLAS, SHERI DENET | SITEONE THERAPEUTICS, INC., CA | $1,081,115 | ZRG1 |
| 2021 | A low-input compatible, end-to-end kitted HiChIP workflow for concurrent analyses of transcriptional protein binding and chromatin interactions toward a mechanistic understanding of gene regulation1R44GM142410-01 | SCHMITT, ANTHONY | ARIMA GENOMICS, INC., CA | $1,074,115 | ZRG1 |
| 2021 | Phase II, Head Up Cardiopulmonary Resuscitation Device2R44HL139184-02A1 | LURIE, KEITH | ADVANCEDCPR SOLUTIONS LLC, MN | $1,069,357 | ZRG1 |
| 2021 | A Biosynthetic Degradable Textile for Soft Tissue Reconstruction2R44GM134778-02A1 | RUPPERT, DAVID | DEEP BLUE MEDICAL ADVANCES, INC., NC | $1,063,767 | ZRG1 |
| 2021 | Mechanism to Promote Safe and Efficient Oral Feeding in Preterm Infants2R44HD092210-02A1 · under PA-19-272 | MATHUR, AMIT MOHANOLEKSY, THOMASPINEDA, ROBERTA | PREEMIE-PACER, LLC, MO | $1,062,573 | ZRG1 |
| 2021 | Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles2R44CA232778-02A1 · under PA-19-272 | ASSOULINE, JOE | NANOMEDTRIX, LLC, IA | $1,043,125 | ZRG1 |
| 2021 | Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy1R44DK127879-01A1 | BEATON, GRAHAMCALCUTT, NIGEL A. | EPIGEN BIOSCIENCES, INC., CA | $1,035,811 | ZRG1 |
| 2021 | Real-time three-dimensional spinal navigation system for bedside lumbar puncture placement1R44NS120798-01A1 | MAULDIN, FRANK WILLIAM | RIVANNA MEDICAL, INC., VA | $1,032,828 | ZRG1 |
| 2021 | Quantitative mapping of combinatorial histone modifications2R44HG010595-02 | BURG, JONATHAN MICHAELKEOGH, MICHAEL-CHRISTOPHERVENTERS, BRYAN J | EPICYPHER, INC., NC | $1,024,752 | ZRG1 |
| 2021 | In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown Adipogenesis2R44DK125193-02 | BOSS, OLIVIER | ENERGESIS PHARMACEUTICALS, INC., MA | $1,018,644 | ZRG1 |
| 2021 | Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases2R44CA221553-02A1 · under PA-19-272 | MARGULIES, BRYAN SAMUEL | ZETAGEN THERAPEUTICS, INC., NY | $1,014,441 | ZRG1 |
| 2021 | A new epigenetic toolbox for inflammation research and drug discovery1R44AI162386-01 | KEOGH, MICHAEL-CHRISTOPHER | EPICYPHER, INC., NC | $1,012,272 | ZRG1 |
| 2021 | Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children2R44HL129577-02A1 · under PA-19-272 | CLIFTON, WILL | POLYVASCULAR CORPORATION, TX | $1,007,115 | ZRG1 |
| 2021 | High channel count electrophysiology and data processing for freely-moving animals2R44MH114783-04 | SHERWOOD, JOHN L | LEAFLABS, LLC, MA | $1,005,444 | ZRG1 |
| 2021 | Rational design of bifunctional protein degrader drugs2R44GM134737-02 | KADIMISETTY, KARTEEK | LIFESENSORS, INC., PA | $1,004,186 | ZRG1 |
| 2021 | Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy1R44CA257799-01A1 | BOMBA, HUNTER NICOLE | CANCER TARGETED TECHNOLOGY, LLC, WA | $1,000,002 | ZRG1 |
| 2021 | A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis1R44AI157031-01 · under PA-19-272 | FANGER, GARY | RISE THERAPEUTICS, LLC, MD | $1,000,000 | ZRG1 |
| 2021 | Massively Multiplexed dsDNA Invasion Arrays1R44AI157322-01 · under PA-19-272 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2021 | Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia1R44AI157719-01 · under PA-19-272 | CRAIGO, JODI K | CYTOAGENTS, INC., PA | $1,000,000 | ZRG1 |
| 2021 | A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products2R44AI138943-03 · under PA-19-272 | BILLINGSLEY, PETER F. | SANARIA, INC., MD | $1,000,000 | ZRG1 |
| 2021 | An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood2R44AI124726-04 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2021 | Immunotherapy of MRSA Osteomyelitis1R44AI155309-01A1 | AMAN, M JAVAD | INTEGRATED BIOTHERAPEUTICS, INC., MD | $1,000,000 | ZRG1 |
| 2021 | Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection1R44AI155308-01A1 | COBURN, GLEN ANDREW | VENATORX PHARMACEUTICALS, INC., PA | $1,000,000 | ZRG1 |
| 2021 | Automating mosquito microdissection for a malaria PfSPZ vaccine2R44AI134500-04A1 | CHAKRAVARTY, SUMANAHOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $1,000,000 | ZRG1 |
| 2021 | Early and accurate diagnosis of pulmonary and extrapulmonary tuberculosis in all patient groups using a circulating pathogen-derived antigen1R44AI162527-01A1 | TOMBLER, THOMAS W | NANOPIN TECHNOLOGIES, INC., LA | $1,000,000 | ZRG1 |
| 2021 | Enabling comprehensive diagnosis of sub-acute infection in chronic respiratory disease via high sensitivity next generation sequencing2R44AI154380-02A1 | MARCUS, ROLAND | PEAK DIAGNOSTIC PARTNERS LLC, CO | $1,000,000 | ZRG1 |
| 2021 | Validation of a Bedside Automated 3D Ultrasound-based Arteriovenous Fistula Cannulation Guidance Solution to Improve AV Fistula Outcomes1R44DK131644-01 | KANG, XIN | SONAVEX, INC., MD | $1,000,000 | ZRG1 |
| 2021 | Everyday Use of Optical Cherenkov Imaging Identifies Adverse Events and Opportunities for Improved Radiation Treatment1R44CA265654-01 | WARE, WILLIAM | DOSEOPTICS, LLC, NH | $999,998 | ZRG1 |
| 2021 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)2R44AI136176-02 | GAREY, KEVIN WYANG, ZHIYONG | FZATA, INC., MD | $999,996 | ZRG1 |
| 2021 | Screening for rAAV transduction enhancers2R44AI125043-03 · under PA-19-272 | BOWLIN, TERRY L. | MICROBIOTIX, INC, MA | $999,976 | ZRG1 |
| 2021 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis2R44AI126987-05A1 | PULSIPHER, ABIGAIL | GLYCOMIRA, LLC, UT | $999,953 | ZRG1 |
| 2021 | Point-of-Care Rapid RNA test for Zika1R44TR003549-01 · under PA-19-272 | CHO, HYUNDAE | CROSSLIFE TECHNOLOGIES, INC., CA | $999,916 | ZRG1 |
| 2021 | Product optimization to commercialize an oral bacteriophage cocktail that prevents cholera in real-world settings2R44AI142960-03 · under PA-19-272 | CAMILLI, ANDREWYEN, MINMIN | PHAGEPRO, INC., MA | $999,585 | ZRG1 |
| 2021 | Parallelized Imaging and Automated Analysis of Zebrafish Assays with a Gigapixel Microscope2R44OD024879-04 | HARFOUCHE, MARK | RAMONA OPTICS, INC., NC | $999,300 | ZRG1 |
| 2021 | Final Preclinical Testing and Formulation of a Scalable, Live-attenuated SARS-CoV-2 Vaccine1R44AI162404-01 | MUELLER, STEFFEN | CODAGENIX, INC., NY | $999,267 | ZRG1 |
| 2021 | Novel therapy for Fragile X syndrome2R44MH115529-03 · under PA-19-272 | MUOTRI, ALYSSON R.TUCCI, FABIO COHEN | EPIGEN BIOSCIENCES, INC., CA | $998,958 | ZRG1 |
| 2021 | Portable electrical nitric oxide generator for treatment of pulmonary hypertension accompanying interstitial lung disease2R44TR001704-03A1 | HALL, GREG | THIRD POLE, INC., MA | $998,712 | ZRG1 |
| 2021 | Immunomodulatory Therapy for Neuropathic Pain2R44NS106850-02 | CHEN, RIDONG | APT THERAPEUTICS, INC., IL | $996,399 | ZRG1 |
| 2021 | A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic1R44AI157081-01 · under PA-19-272 | LAFLEUR, MICHAEL | ARIETIS, MA | $995,100 | ZRG1 |
| 2021 | Development of VNLG-152R as novel therapeutic for triple negative breast cancer1R44CA257495-01A1 | NJAR, VINCENT COLLINS OFUKARAMAMURTHY, VIDYA P | ISOPRENE PHARMACEUTICALS, INC., MD | $995,100 | ZRG1 |
| 2021 | Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation1R44OD030205-01 · under PA-19-272 | VARADHACHARY, ATULVEGA, STEPHANIE PRISCILLA | FANNIN PARTNERS, LLC, TX | $993,974 | ZRG1 |
| 2021 | An Intraperitoneal Insulin Delivery System for Management of Type 1 Diabetes1R44DK129075-01A1 | BURNETT, DANIEL ROGERSHANSON, CHRISTOPHER | PERIKINETICS INC, TX | $993,339 | ZRG1 |
| 2021 | Endoscope development for the clinical use of near infrared fluorescence molecular probes in the GI tract1R44CA261318-01A1 | MCMORROW, GERALD | VERAVANTI, INC., WA | $993,178 | ZRG1 |
| 2021 | Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes2R44DK121598-02A1 | LERNER, DANIEL JSAH, RAJAN | SENSEION THERAPEUTICS, INC., MO | $993,178 | ZRG1 |
| 2021 | Subcutaneous Drug Development for Portal Hypertension Ascites2R44DK103553-03A1 | CASTILLO, GERARDO M. | PHARMAIN CORPORATION, WA | $992,469 | ZRG1 |
| 2021 | Rapid antimicrobial susceptibility testing directly from urine specimens1R44AI157672-01A1 | STRAUS, DON | FIRST LIGHT DIAGNOSTICS , INC., MA | $991,573 | ZRG1 |
| 2021 | Noninvasive biomarkers for gastrointestinal disease in preterm infants2R44HD095779-02 | BUCKLEY, REBECCA SKIM, SUNYOUNG | CHOSEN DIAGNOSTICS, INC., LA | $991,043 | ZRG1 |
| 2021 | Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases1R44AI165119-01 | ROTHSTEIN, JAY L | IMMUNEXT, INC., NH | $990,946 | ZRG1 |
| 2021 | Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases2R44AI141281-02 | LOWERY, ROBERT G | BELLBROOK LABS, LLC, WI | $988,840 | ZRG1 |
Showing the 200 most recent of 5,656 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.